Improved Prognosis And Treatment Of Lung Cancer Could Result From UAB Research

Main Category: Lung Cancer
Also Included In: Smoking / Quit Smoking;  Biology / Biochemistry;  Diabetes
Article Date: 08 Jan 2008 - 5:00 PDT

email to a friend   printer friendly   view / write opinions   rate article

A group of scientists led by Professor Xavier Pares of the Department of Biochemistry and Molecular Biology at Universitat Autonoma de Barcelona, has published research on AKR1B10, an enzyme that is detected in large quantities only in lung cancers, particularly those caused by smoking. This enzyme can appear even when the cancer has not yet developed and lesions are precancerous. Thus this molecule would serve as a good marker in the diagnosis and prognosis of the disease. Moreover, its activity could play a relevant role in the development of lung cancer, which makes the research of great interest for potential future therapeutical applications as well.

According to researchers, both the experiments using test tubes and cell cultures revealed that the enzyme lowers the levels of the most active form of vitamin A (retinoic acid), a strong anticancerous agent. This is achieved by its strong retinal reductase activity, which favours chemical reduction transformation, thus causing retinal, the precursor of retinoic acid, to transform into its least active form, retinol.

Retinoic acid is present in several biological processes - from fetus development to cell proliferation and differentiation - by controlling the expression of certain genes. The reduction of this acid within cells, which is precisely the effect produced by the enzyme under study, is linked directly to the lack of cell differentiation and therefore favours the development of the cancer. In order to discover why the enzyme acts this way, scientists obtained and studied its three-dimensional structure and located the elements responsible for its role in the onset of cancer among smokers. The identification of these structural elements makes it possible to create a specific design for drugs that can treat this disease. In fact, researchers were able to observe how the substance tolrestat, used as an inhibitor of the enzyme AKR1B1, or aldose reductase, responsible for many secondary complications of diabetes, also worked to inhibit the activity of the enzyme AKR1B10. Since both enzymes contain similar structures, research was carried out on its possible applications in the treatment of diabetes.

----------------------------
Article adapted by Medical News Today from original press release.
----------------------------

The research, published in the prestigious American journal Proceedings of the National Academy of Sciences (PNAS), was directed by Xavier Parés and Jaume Farrés of the UAB Department of Biochemistry and Molecular Biology, with the collaboration of scientists from the Biomedical Research Institute of the Science Park of Barcelona (PCB), the Institute of Molecular Biology of Barcelona (CSIC), the Catalan Institute for Research and Advanced Studies (ICREA), and the Department of Organic Chemistry of the University of Vigo, Galicia.

Source: Xavier Parés
Universitat Autonoma de Barcelona